O	0	1	A
O	2	13	multicenter
O	14	24	randomized
O	25	30	phase
O	31	33	II
O	34	39	study
O	40	42	of
B-intervention	43	53	sequential
I-intervention	54	64	epirubicin
I-intervention	64	65	/
I-intervention	65	81	cyclophosphamide
I-intervention	82	90	followed
I-intervention	91	93	by
I-intervention	94	103	docetaxel
I-intervention	104	108	with
I-intervention	109	111	or
I-intervention	112	119	without
I-intervention	120	129	celecoxib
I-intervention	130	132	or
I-intervention	133	144	trastuzumab
O	145	154	according
O	155	157	to
O	158	162	HER2
O	163	169	status
O	169	170	,
O	171	173	as
O	174	181	primary
O	182	194	chemotherapy
O	195	198	for
O	199	208	localized
O	209	217	invasive
O	218	224	breast
O	225	231	cancer
O	232	240	patients
O	240	241	.

O	242	244	To
O	245	251	assess
O	252	256	anti
O	256	257	-
O	257	262	tumor
O	263	271	activity
O	272	274	of
O	275	285	sequential
O	286	296	epirubicin
O	296	297	/
O	297	313	cyclophosphamide
O	314	322	followed
O	323	325	by
O	326	335	docetaxel
O	336	340	with
O	341	344	the
O	345	355	randomized
O	356	364	addition
O	365	367	of
O	368	377	celecoxib
O	378	380	in
O	381	385	HER2
O	386	394	negative
O	395	403	patients
O	404	406	or
O	407	418	trastuzumab
O	419	421	in
O	422	426	HER2
O	427	435	positive
O	436	444	patients
O	444	445	.

O	446	450	From
O	451	454	May
O	455	459	2004
O	460	464	till
O	465	472	October
O	473	477	2007
O	477	478	,
B-total-participants	479	482	340
B-eligibility	483	491	patients
I-eligibility	492	496	with
I-eligibility	497	502	stage
I-eligibility	503	505	II
I-eligibility	506	509	and
I-eligibility	510	513	III
I-eligibility	514	520	breast
I-eligibility	521	535	adenocarcinoma
I-eligibility	535	536	,
I-eligibility	537	547	ineligible
I-eligibility	548	551	for
I-eligibility	552	558	breast
I-eligibility	559	569	conserving
I-eligibility	570	577	surgery
O	577	578	,
O	579	587	received
O	588	593	eight
O	594	604	sequential
O	605	610	three
O	611	617	weekly
O	618	624	cycles
O	625	627	of
O	628	630	EC
O	630	631	-
O	631	632	D
O	633	634	[
O	634	644	epirubicin
O	645	646	(
O	646	648	75
O	649	651	mg
O	651	652	/
O	652	653	m
O	653	654	(
O	654	655	2
O	655	656	)
O	656	657	)
O	657	658	-
O	658	674	cyclophosphamide
O	675	676	(
O	676	679	750
O	680	682	mg
O	682	683	/
O	683	684	m
O	684	685	(
O	685	686	2
O	686	687	)
O	687	688	)
O	689	692	for
O	693	697	four
O	698	704	cycles
O	705	713	followed
O	714	716	by
O	717	726	docetaxel
O	727	728	(
O	728	731	100
O	732	734	mg
O	734	735	/
O	735	736	m
O	736	737	(
O	737	738	2
O	738	739	)
O	739	740	)
O	741	744	for
O	745	749	four
O	750	756	cycles
O	756	757	]
O	757	758	.

B-eligibility	759	763	HER2
I-eligibility	763	764	-
I-eligibility	764	772	negative
I-eligibility	773	781	patients
O	782	783	(
O	783	784	N
O	785	786	=
B-total-participants	787	790	220
O	790	791	)
O	792	796	were
O	797	807	randomized
O	808	810	to
O	811	818	receive
O	819	832	concomitantly
O	833	837	with
O	838	847	docetaxel
O	848	857	celecoxib
O	858	861	800
O	862	864	mg
O	864	865	/
O	865	868	day
O	869	875	during
O	876	882	cycles
O	883	884	5
O	884	885	-
O	885	886	8
O	887	889	or
B-control	890	892	no
I-control	893	903	additional
I-control	904	913	treatment
O	913	914	,
O	915	920	while
O	921	925	HER2
O	925	926	-
O	926	934	positive
O	935	943	patients
O	944	953	confirmed
O	954	956	by
O	957	961	FISH
O	962	963	(
O	963	964	N
O	965	966	=
B-total-participants	967	970	120
O	970	971	)
O	972	976	were
O	977	987	randomized
O	988	990	to
O	991	1002	trastuzumab
O	1003	1014	concomitant
O	1015	1017	to
O	1018	1027	docetaxel
O	1028	1029	(
O	1029	1030	8
O	1031	1033	mg
O	1033	1034	/
O	1034	1036	kg
O	1037	1041	then
O	1042	1043	6
O	1044	1046	mg
O	1046	1047	/
O	1047	1049	kg
O	1050	1052	IV
O	1053	1058	every
O	1059	1060	3
O	1061	1066	weeks
O	1066	1067	)
O	1068	1070	or
O	1071	1073	no
O	1074	1084	additional
O	1085	1097	preoperative
O	1098	1107	treatment
O	1107	1108	.

B-outcome	1109	1111	In
I-outcome	1112	1115	the
I-outcome	1116	1120	HER2
I-outcome	1121	1129	negative
I-outcome	1130	1135	group
O	1135	1136	,
B-outcome	1137	1140	pCR
O	1141	1142	(
O	1142	1147	grade
O	1148	1149	1
O	1150	1153	and
O	1154	1155	2
O	1156	1158	of
O	1159	1169	Chevallier
O	1169	1170	'
O	1170	1171	s
O	1172	1186	classification
O	1186	1187	)
O	1188	1191	was
O	1192	1200	observed
O	1201	1203	in
B-iv-bin-percent	1204	1206	11
I-iv-bin-percent	1206	1207	.
I-iv-bin-percent	1207	1208	5
O	1209	1212	and
B-cv-bin-percent	1213	1215	13
I-cv-bin-percent	1215	1216	%
O	1217	1219	of
O	1220	1228	patients
O	1229	1236	treated
O	1237	1244	without
O	1245	1248	and
O	1249	1253	with
O	1254	1265	neoadjuvant
O	1266	1275	Celecoxib
O	1275	1276	,
O	1277	1289	respectively
O	1289	1290	.

B-outcome	1291	1293	In
I-outcome	1294	1297	the
I-outcome	1298	1302	HER2
I-outcome	1303	1311	positive
I-outcome	1312	1317	group
O	1317	1318	,
B-outcome	1319	1322	pCR
I-outcome	1323	1327	rate
O	1328	1335	reached
B-iv-bin-percent	1336	1338	26
I-iv-bin-percent	1338	1339	%
O	1340	1342	in
O	1343	1348	those
O	1349	1352	who
O	1353	1361	received
O	1362	1373	neoadjuvant
O	1374	1385	trastuzumab
O	1386	1392	versus
B-cv-bin-percent	1393	1395	19
I-cv-bin-percent	1395	1396	%
O	1397	1399	in
O	1400	1403	the
O	1404	1410	others
O	1410	1411	.

O	1412	1417	There
O	1418	1421	was
O	1422	1424	no
O	1425	1435	unexpected
B-outcome	1436	1444	toxicity
I-outcome	1444	1445	,
I-outcome	1446	1448	no
I-outcome	1449	1456	cardiac
I-outcome	1457	1465	toxicity
I-outcome	1465	1466	,
I-outcome	1467	1470	and
I-outcome	1471	1473	no
I-outcome	1474	1479	toxic
I-outcome	1480	1485	death
O	1485	1486	.

O	1487	1493	Triple
O	1494	1502	negative
O	1503	1509	breast
O	1510	1517	cancers
O	1518	1528	experience
O	1529	1532	the
O	1533	1540	highest
B-outcome	1541	1544	pCR
I-outcome	1545	1549	rate
O	1550	1552	of
O	1553	1555	30
O	1555	1556	%
O	1556	1557	.

O	1558	1567	Celecoxib
O	1568	1570	is
O	1571	1574	not
O	1575	1581	likely
O	1582	1584	to
O	1585	1592	improve
B-outcome	1593	1596	pCR
I-outcome	1597	1602	rates
O	1603	1605	in
O	1606	1614	addition
O	1615	1617	to
O	1618	1620	EC
O	1620	1621	-
O	1621	1622	D
O	1623	1625	in
O	1626	1634	patients
O	1635	1639	with
O	1640	1644	HER2
O	1644	1645	-
O	1645	1653	negative
O	1654	1659	tumor
O	1659	1660	.

O	1661	1663	In
O	1664	1668	HER2
O	1668	1669	-
O	1669	1677	positive
O	1678	1683	tumor
O	1684	1692	patients
O	1692	1693	,
O	1694	1705	trastuzumab
O	1706	1711	added
O	1712	1714	to
O	1715	1718	ECD
O	1719	1724	leads
O	1725	1727	to
O	1728	1737	increased
O	1738	1741	pCR
O	1742	1747	rates
O	1747	1748	.

O	1749	1751	It
O	1752	1755	was
O	1756	1759	the
O	1760	1764	only
O	1765	1776	combination
O	1777	1779	to
O	1780	1787	deserve
O	1788	1795	further
O	1796	1801	study
O	1802	1811	according
O	1812	1814	to
O	1815	1818	the
O	1819	1822	two
O	1822	1823	-
O	1823	1828	stage
O	1829	1836	Fleming
O	1836	1837	'
O	1837	1838	s
O	1839	1845	design
O	1846	1850	used
O	1851	1853	in
O	1854	1858	this
O	1859	1864	trial
O	1864	1865	.
